Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

You may be eligible if

• Patients must have received prior treatment which included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).
• Patients must have received no more than two prior chemotherapy regimens. Patients who have not received treatment for metastatic disease must have relapsed within one year.
• Patients may not have any history of brain and/or leptomeningeal metastases.
• Patients may not have Grade 2 or worse neuropathy at the time of study entry.
• Patients may not have had prior treatment with any epothilones and/or capecitabine (i.e. Xeloda)